Lupus nephritis treatment: a comprehensive overview of recent meta-analyses and future directions.
High-dose glucocorticoids improve complete renal remission in lupus nephritis.
Lupus nephritis treatment: a comprehensive overview of recent meta-analyses and future directions.
This review summarizes recent findings from meta-analyses on lupus nephritis (LN) therapies to promote precision medicine and address the challenge of fragmented evidence.
A literature search identified 34 relevant meta-analyses published between January 2021 and March 2025.
However, rituximab, while effective, carries a higher infection risk (SUCRA = 74.98%).
The combination of tacrolimus and mycophenolate mofetil doubled the CR rate compared to monotherapy (OR = 2.85), but requires monitoring for creatinine elevation.
The combination of Tripterygium glycosides and Western medicine increased the CR rate by 61% (RR = 1.61), while Astragalus-containing Chinese herbal medicine significantly reduced proteinuria (SMD = 0.51), highlighting the value of traditional Chinese medicine in enhancing efficacy and reducing toxicity.
In conclusion, this review provides a comprehensive overview of recent research on LN treatment, offering evidence-based support for clinical decision-making and points out directions for future research.